Maxwell Skor
Stock Analyst at Morgan Stanley
(4.36)
# 1,288
Out of 5,053 analysts
253
Total ratings
52.7%
Success rate
14.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maxwell Skor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHVS Pharvaris | Rated: Buy | $62 | $30.02 | +106.53% | 96 | Oct 12, 2026 | |
| INSM Insmed | Reiterated: Buy | $218 | $96.79 | +125.23% | 32 | Oct 9, 2026 | |
| ASND Ascendis Pharma | Rated: Buy | $273 | $223.21 | +22.31% | 33 | Oct 5, 2026 | |
| RARE Ultragenyx Pharmaceutical | Rated: Hold | $18 → $20 | $14.92 | +34.05% | 15 | Sep 21, 2026 | |
| CRSP CRISPR Therapeutics AG | Reiterated: Hold | $60 | $50.10 | +19.76% | 3 | Aug 28, 2026 | |
| ADAG Adagene | Reiterated: Hold | n/a | $2.46 | - | 7 | Aug 17, 2026 | |
| BCYC Bicycle Therapeutics | Reiterated: Hold | n/a | $3.63 | - | 9 | Aug 17, 2026 | |
| MNPR Monopar Therapeutics | Rated: Buy | $115 → $130 | $72.08 | +80.36% | 4 | Aug 17, 2026 | |
| SANA Sana Biotechnology | Rated: Buy | $12 | $2.41 | +397.93% | 4 | Aug 17, 2026 | |
| TCRX TScan Therapeutics | Reiterated: Hold | n/a | $0.2167 | - | 7 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $13 | $7.00 | +85.71% | 1 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $6 → $7 | $4.98 | +40.56% | 11 | Aug 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $103 | $61.62 | +67.15% | 21 | Jul 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9.5 → $3.55 | $0.646 | n/a | 10 | Nov 20, 2024 |
Pharvaris
Oct 12, 2026
Rated: Buy
Price Target: $62
Current: $30.02
Upside: +106.53%
Insmed
Oct 9, 2026
Reiterated: Buy
Price Target: $218
Current: $96.79
Upside: +125.23%
Ascendis Pharma
Oct 5, 2026
Rated: Buy
Price Target: $273
Current: $223.21
Upside: +22.31%
Ultragenyx Pharmaceutical
Sep 21, 2026
Rated: Hold
Price Target: $18 → $20
Current: $14.92
Upside: +34.05%
CRISPR Therapeutics AG
Aug 28, 2026
Reiterated: Hold
Price Target: $60
Current: $50.10
Upside: +19.76%
Adagene
Aug 17, 2026
Reiterated: Hold
Price Target: n/a
Current: $2.46
Upside: -
Bicycle Therapeutics
Aug 17, 2026
Reiterated: Hold
Price Target: n/a
Current: $3.63
Upside: -
Monopar Therapeutics
Aug 17, 2026
Rated: Buy
Price Target: $115 → $130
Current: $72.08
Upside: +80.36%
Sana Biotechnology
Aug 17, 2026
Rated: Buy
Price Target: $12
Current: $2.41
Upside: +397.93%
TScan Therapeutics
Aug 17, 2026
Reiterated: Hold
Price Target: n/a
Current: $0.2167
Upside: -
Aug 13, 2026
Initiated Coverage: Buy
Price Target: $13
Current: $7.00
Upside: +85.71%
Aug 13, 2026
Rated: Hold
Price Target: $6 → $7
Current: $4.98
Upside: +40.56%
Jul 23, 2026
Rated: Buy
Price Target: $103
Current: $61.62
Upside: +67.15%
Nov 20, 2024
Reiterated: Buy
Price Target: $9.5 → $3.55
Current: $0.646
Upside: n/a